Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Sells $173,920.00 in Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director Adeoye Olukotun sold 2,000 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total transaction of $173,920.00. Following the completion of the transaction, the director directly owned 31,600 shares of the company’s stock, valued at approximately $2,747,936. This trade represents a 5.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Arrowhead Pharmaceuticals Stock Performance

Shares of Arrowhead Pharmaceuticals stock traded down $1.94 during trading on Thursday, hitting $87.47. 896,837 shares of the stock were exchanged, compared to its average volume of 2,359,317. The company has a current ratio of 5.90, a quick ratio of 5.90 and a debt-to-equity ratio of 1.77. The company has a fifty day moving average price of $82.33 and a 200-day moving average price of $72.64. The stock has a market capitalization of $12.32 billion, a price-to-earnings ratio of -38.88 and a beta of 1.27. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $19.82 and a 1-year high of $95.49.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The firm had revenue of $75.25 million during the quarter, compared to analyst estimates of $44.17 million. During the same quarter last year, the business posted ($1.26) earnings per share. The company’s revenue for the quarter was up 171.0% on a year-over-year basis. As a group, equities analysts predict that Arrowhead Pharmaceuticals, Inc. will post -3.51 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on ARWR. B. Riley Financial lifted their target price on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Royal Bank Of Canada increased their price target on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Chardan Capital raised their price target on Arrowhead Pharmaceuticals from $90.00 to $115.00 and gave the company a “buy” rating in a report on Wednesday, July 22nd. HC Wainwright lifted their price objective on shares of Arrowhead Pharmaceuticals from $115.00 to $120.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, Wall Street Zen upgraded shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $97.33.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Tsfg LLC bought a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter worth approximately $25,000. Optiver Holding B.V. grew its holdings in Arrowhead Pharmaceuticals by 83.8% in the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 186 shares in the last quarter. Versant Capital Management Inc grew its holdings in Arrowhead Pharmaceuticals by 285.1% in the 2nd quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 248 shares in the last quarter. Carolina Wealth Advisors LLC increased its position in Arrowhead Pharmaceuticals by 80.6% during the 2nd quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock worth $28,000 after buying an additional 154 shares during the period. Finally, iSAM Funds UK Ltd bought a new position in Arrowhead Pharmaceuticals during the 3rd quarter worth $29,000. Institutional investors own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.